Home
Board of Directors
Membership
Apply for INA Membership
Account Details
TOXINS 2024
FAQs
Previous Congresses
TOXINS 2022
TOXINS 2021 Virtual
TOXINS 2019
General Information
Organizing Committee
Speakers
Conference Program
EACCME Statement
TOXINS 101 Workshop
Hands-on Ultrasound Guidance Workshop
Topics to be Addressed
Sponsors
Venue & Housing Information
Registration Information
Satellite Symposia
TOXINS 2019 Registration (closed)
Abstract Submission (closed)
Poster Presentation Details
Sponsorship/Exhibitor Opportunities
Copenhagen Travel
TOXINS 2017
General Information
Organizing Committee
Conference Program
EACCME Statement
Venue & Housing Information
Registration Information
Satellite Symposia
TOXINS 2017 Registration (closed)
Abstract Submission (closed)
Exhibitor Opportunities
Sponsors
TOXINS 2015
General Information
Organizing Committee
Conference Program
CME/CPD Information
Venue & Housing Information
Satellite Symposia
Registration Information
TOXINS 2015 Registration (closed)
Abstract Submission (closed)
Exhibitor Opportunities
TAP Portugal Airline
Sponsors
TOXINS 2012
General Information
Conference Program
CME/CPD Information
Calendar
About
Contact
Thursday – Clinical Track 1A
Name Badge ID
(Required)
Full Name
(Required)
Enter your first and last names as you would like them to appear on your certificates.
First
Last
Email
(Required)
Enter the email you used to register for TOXINS 2022.
Please evaluate the speakers
Overall Evaluation
Topic and Speaker(s)
Excellent
Good
Fair
Poor
What's New? BoNT Clinical Trial Update: Adult Spasticity
Alberto Esquenazi (USA)
Gait Pattern Recognition and Muscle Selection for BoNT Injections
Alberto Esquenazi (USA)
What Are We Missing? It’s More Than Injections
Laura Wiggs (USA)
What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively?
Anthony Ward (UK)
Presentation free of commercial bias?
Yes
No
What's New? BoNT Clinical Trial Update: Adult Spasticity
Alberto Esquenazi (USA)
Gait Pattern Recognition and Muscle Selection for BoNT Injections
Alberto Esquenazi (USA)
What Are We Missing? It’s More Than Injections
Laura Wiggs (USA)
What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively?
Anthony Ward (UK)
If you answered “No, this presentation was not free of commercial bias”, on any of the above, please explain your reason(s).
Applicable to my practice/research
Yes
No
What's New? BoNT Clinical Trial Update: Adult Spasticity
Alberto Esquenazi (USA)
Gait Pattern Recognition and Muscle Selection for BoNT Injections
Alberto Esquenazi (USA)
What Are We Missing? It’s More Than Injections
Laura Wiggs (USA)
What Are the Early Risk Factors for Disabling Spasticity—Does BoNT Treatment Reduce the Risk Effectively?
Anthony Ward (UK)
This activity should improve my
Strongly disagree
Disagree
Neutral
Agree
Strongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care
Comments
Member Login
Username
(Required)
Password
(Required)
Remember Me
Not a member
Forgot Password?
TOXINS 2022
Abstract Submission (closed)
CME Information
Conference Program
COVID-19 Information and Policies
General Information
Industry Sponsored Sessions
Letter from the Chair
Organizing Committee
Poster Presentation Details
Registration Information
Registration (closed)
Schedule of Events
Speakers
Sponsors
Sponsorship/Exhibitor Opportunities
Topics of Discussion
Venue & Housing Information
Join Our Mailing List
Click here
to sign up, and then manage your subscription.
We use cookies on our website to provide you with the best possible user experience. By continuing to use our website or services, you agree to their use.
OK